Summary of findings:
Vaccine effectiveness: The two-dose Pfizer-BioNTech vaccination provides 70% protection against severe complications of COVID-19 requiring hospitalization, and 33% protection against COVID-19 infection, during the current Omicron wave.
Reinfection risk: For individuals who have had COVID-19 previously, the risk of reinfection with Omicron is significantly higher, relative to prior variants.
Severity: The risk of hospital admission among adults diagnosed with COVID-19 is 29% lower for the Omicron variant infection compared to infections involving the D614G mutation in South Africa’s first wave in mid-2020, after adjusting for vaccination status
Children: Despite very low absolute incidence, preliminary data suggests that children have a 20% higher risk of hospital admission in Omicron-led fourth wave in South Africa, relative to the D614G-led first wave.
Read the complete press release at Discovery Health
- UAE reports Middle East respiratory syndrome coronavirus (MERS-CoV) case in Abu Dhabi region
- China: Expert expects country to achieve herd immunity by end of year, 1st Omicron case reported
- Boris Johnson: ‘A tidal wave of Omicron is coming. Get Boosted Now’
- Argentina: Congenital syphilis cases in Córdoba up 68 percent in 2021
- Brazil: Eight human yellow fever cases, including 3 deaths in Santa Catarina
- Sweden flu season underway, warns ‘there is a risk that it will be intense’
- Finland reports 11 additional Omicron cases, Brings total to 20
- Elimination of transmission of onchocerciasis, or river blindness in Niger
- Monkeypox outbreak declared in Maniema, DRC
- Ivermectin and dafachronic acid combo identified as possible cure for Strongyloidiasis
- Omicron: Previous infection and vaccination will have some ‘stronger than basic’ defense against variant
- Ohio reports first Omicron cases